Gene Therapy in Retinal Dystrophies

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Inherited retinal dystrophies (IRDs) are genetically diverse degenerative eye conditions.
• Despite advances, genetic mutations remain unidentified in approximately one-third of IRD cases.
• The retina's unique characteristics make it a prime target for gene therapy.

Purpose of the Study:

• To review current knowledge on gene therapy for IRDs, including methodological challenges and future directions.
• To present the latest advancements and state-of-the-art in ongoing clinical trials for IRD gene therapy.
• To highlight the impact of genome sequencing on IRD diagnosis, prognosis, and therapeutic development.

Main Methods:

• Review of current literature on gene therapy for inherited retinal dystrophies.
• Analysis of methodological issues and translational challenges in preclinical and clinical settings.
• Compilation and illustration of the current state of clinical trials for IRD gene therapy.

Main Results:

• Genome sequencing advancements have revolutionized IRD diagnosis and identified new therapeutic targets.
• The development of gene therapy approaches is progressing, with several clinical trials underway.
• The approval of Luxturna signifies a new era in treating IRDs, specifically Leber congenital amaurosis.

Conclusions:

• Gene therapy holds significant promise for treating IRDs, driven by genetic discoveries and technological progress.
• Ongoing clinical trials are crucial for translating gene therapy potential into effective treatments for various IRDs.
• Despite challenges, the retina remains a key focus for gene therapy, with continued research expected to yield further breakthroughs.